艾多沙班在房颤合并PCI患者中按ACS或CCS表现的安全性分析
该研究为ENTRUST-AF PCI试验的预设亚组分析,按急性冠脉综合征(ACS)或慢性冠脉综合征(CCS)分层,比较艾多沙班联合P2Y12抑制剂与维生素K拮抗剂(VKA)方案的安全性和有效性。结果显示,无论临床表现为ACS还是CCS,艾多沙班方案与VKA方案在出血和缺血事件方面均无显著差异,且交互作用不显著。
要点
- ACS亚组12个月主要出血事件:艾多沙班组15.2% vs VKA组20.3%(HR 0.73,95%CI 0.59-1.02,P=0.063)。
- CCS亚组主要出血事件:艾多沙班组19.0% vs VKA组19.9%(HR 0.94,95%CI 0.68-1.31,P=0.708)。
- 主要次要终点在ACS和CCS亚组中均无显著差异,交互作用P值分别为0.2741和0.5573。
核心结论
- 在房颤合并PCI患者中,无论表现为ACS还是CCS,艾多沙班方案与VKA方案相比,安全性和缺血事件疗效均一致。
研究设计与样本
- ENTRUST-AF PCI试验的预设亚组分析,参与者按1:1随机分配至艾多沙班或VKA方案,并按ACS(艾多沙班n=388,VKA n=389)与CCS(艾多沙班n=363,VKA n=366)分层。
主要发现
- ACS患者12个月主要出血事件:艾多沙班组59例(15.2%) vs VKA组79例(20.3%),HR 0.73(95%CI 0.59-1.02),P=0.063。
- CCS患者主要出血事件:艾多沙班组69例(19.0%) vs VKA组73例(19.9%),HR 0.94(95%CI 0.68-1.31),P=0.708。
- ACS患者主要次要终点:艾多沙班组33例(8.5%) vs VKA组28例(7.2%),HR 1.16(95%CI 0.70-1.92)。
- CCS患者主要次要终点:艾多沙班组16例(4.4%) vs VKA组18例(4.9%),HR 0.91(95%CI 0.47-1.78)。
- 出血事件的交互作用P=0.2741,主要次要终点的交互作用P=0.5573。
临床怎么用
- 对于房颤合并PCI患者,艾多沙班联合P2Y12抑制剂方案可作为VKA方案的替代选择,且无需根据ACS或CCS表现调整策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). METHODS AND RESULTS: In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n = 388, VKA n = 389) vs. CCS (edoxaban n = 363, VKA = 366). Participants received edoxaban 60 mg once-daily plus a P2Y12 inhibitor for 12 months, or VKA combined with a P2Y12 inhibitor and aspirin 100 mg (for 1-12 months). The primary bleeding endpoint at 12 months occurred in 59 (15.2%) vs. 79 (20.3%) ACS patients [hazard ratio (HR): 0.73, 95% confidence interval (CI): 0.59-1.02, P = 0.063], and in 69 (19.0%) vs. 73 (19.9%) CCS patients (HR: 0.94, 95%CI: 0.68-1.31, P = 0.708) with edoxaban- and VKA-based therapy, respectively [P for interaction (P-int) = 0.2741]. The main secondary endpoint (composite of CV death, myocardial infarction, stroke, systemic embolic events, or definite stent thrombosis) in ACS patients was 33 (8.5%) vs. 28 (7.2%) (HR: 1.16, 95%CI: 0.70-1.92), compared with 16 (4.4%) vs. 18 (4.9%) (HR: 0.91, 95%CI: 0.47-1.78) CCS patients with edoxaban and VKA-based therapy, respectively (P-int = 0.5573). CONCLUSIONS: In patients with AF who underwent PCI, the edoxaban-based regimen, as compared with VKA-based regimen, provides consistent safety and similar efficacy for ischaemic events in patients with AF regardless of their clinical presentation.
引用
- Vranckx P, Valgimigli M, Eckardt L, et al. Edoxaban in atrial fibrillation patients with percutaneous coronary intervention by acute or chronic coronary syndrome presentation: a pre-specified analysis of the ENTRUST-AF PCI trial. Eur Heart J. 2020. PMID: 32860041. doi:10.1093/eurheartj/ehaa617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。